High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study.

abstract：:PSC-833, a non immunosuppressive analogue of cyclosporin A, is an effective modulator of the multidrug-resistant tumor phenotype. Since both PSC-833 and cyclosporin A also enhance the cytotoxicity of VP-16 against drug sensitive L1210 leukemia cells in vitro we compared these agents as modulators of VP-16 efficacy in ...

journal_title：Cancer chemotherapy and pharmacology

authors： Slater LM,Sweet P,Stupecky M,Osann K

更新日期：1997-01-01 00:00:00

abstract：PURPOSE:The aim was to investigate in patients receiving doxorubicin whether any alteration in myocardial oxidative metabolism or blood flow as assessed by positron emission tomography (PET) could be observed either after the first dose of the drug, or during its chronic administration. METHODS:Six female non-heart-fa...

journal_title：Cancer chemotherapy and pharmacology

authors： Nony P,Guastalla JP,Rebattu P,Landais P,Lievre M,Bontemps L,Itti R,Beaune J,Andre-Fouet X,Janier M

更新日期：2000-01-01 00:00:00

abstract：:The orally bioavailable matrix metalloproteinase inhibitor MMI270 reduces tumour growth metastasis in preclinical models. We assessed the feasibility and pharmacokinetic interactions of combining MMI270 with 5-fluorouracil (5-FU) and folinic acid (FA). Entered into the study were 33 patients with advanced colorectal c...

journal_title：Cancer chemotherapy and pharmacology

authors： Eatock M,Cassidy J,Johnson J,Morrison R,Devlin M,Blackey R,Owen S,Choi L,Twelves C

更新日期：2005-01-01 00:00:00

abstract：:Eighteen previously untreated patients with advanced unresectable or metastatic soft-tissue sarcomas (STS) and two patients with locally invasive thymoma were treated with a combination of adriamycin (ADM) 80 mg/m2 on day 1 and cis-platinum (DDP) 120 mg/m2 on day 1. The regimen was repeated at 4-weeks intervals. In ST...

journal_title：Cancer chemotherapy and pharmacology

authors： Klippstein TH,Mitrou PS,Kochendörfer KJ,Bergmann L

更新日期：1984-01-01 00:00:00

abstract：:Levels of radioactivity and total anthracycline fluorescence in tissues of A/JAX mice were compared 1 h after IV administration of unlabeled or [14C]-labeled AD 32 (50 mg/kg). Highest levels of both fluorescence and radioactivity were found in the small intestine (including contents) and liver, a result consistent wit...

journal_title：Cancer chemotherapy and pharmacology

authors： Israel M,Karkowsky AM,Khetarpal VK

更新日期：1981-01-01 00:00:00

abstract：:N2,N4,N6-Trihydroxymethyl-N2,N4,N6-trimethylmelamine (Trimelamol) is a water-soluble synthetic s-triazine which, unlike hexamethylmelamine (HMM) and pentamethylmelamine (PMM), does not require metabolic activation. The physico-chemical characteristics of Trimelamol were studied with the aim of overcoming the problems ...

journal_title：Cancer chemotherapy and pharmacology

authors： Rutty CJ,Judson IR,Abel G,Goddard PM,Newell DR,Harrap KR

更新日期：1986-01-01 00:00:00

abstract：PURPOSE:Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent due to its selective cytotoxicity to transformed cells. However, most human hepatocellular carcinomas (HCC) develop resistance to TRAIL. Thus, there is an urgent need to investigate the molecular targets and the unde...

journal_title：Cancer chemotherapy and pharmacology

authors： Wang G,Zhan Y,Wang H,Li W

更新日期：2012-03-01 00:00:00

abstract：BACKGROUND/AIMS:Treatment responses of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remain unacceptably low and treatment modalities are limited. We compared the efficacy and safety of sorafenib and hepatic arterial infusion chemotherapy (HAIC). METHODS:In this randomized, prospecti...

journal_title：Cancer chemotherapy and pharmacology

authors： Choi JH,Chung WJ,Bae SH,Song DS,Song MJ,Kim YS,Yim HJ,Jung YK,Suh SJ,Park JY,Kim DY,Kim SU,Cho SB

更新日期：2018-09-01 00:00:00

abstract：PURPOSE:To investigate the safety of intravenous topotecan monotherapy for relapsed small cell lung cancer (SCLC) patients with pre-existing interstitial lung disease (ILD). METHODS:A total of 77 patients who received topotecan for the treatment of relapsed SCLC between April 2007 and April 2014 were reviewed. Patient...

journal_title：Cancer chemotherapy and pharmacology

authors： Enomoto Y,Inui N,Imokawa S,Karayama M,Hasegawa H,Ozawa Y,Matsui T,Yokomura K,Suda T

更新日期：2015-09-01 00:00:00

abstract：PURPOSE:To determine the growth inhibitory effects of mifepristone on endometrial cancer cell growth and evaluate its effect on apoptosis using HEC-1-A and Ishikawa human endometrial cancer cell lines. METHODS:The human endometrial cancer cell lines, HEC-1-A and Ishikawa, were cultured in vitro. MTT assays were comple...

journal_title：Cancer chemotherapy and pharmacology

authors： Navo MA,Smith JA,Gaikwad A,Burke T,Brown J,Ramondetta LM

更新日期：2008-08-01 00:00:00

abstract：PURPOSE:By a scaffold shortening strategy, a small series of retinoidal amides fenretinide (4-HPR) analogs have been synthesized from α, β-ionones and tested for their antiproliferative and differentiating activities, and antioxidant effect. METHODS:The antiproliferative activity and triggering of apoptosis of our sho...

journal_title：Cancer chemotherapy and pharmacology

authors： Anzaldi M,Viale M,Macciò C,Castagnola P,Oliveri V,Rosano C,Balbi A

更新日期：2017-04-01 00:00:00

abstract：:We compared the safety and efficacy in mice with peritoneal carcinomatosis of two etoposide formulations: an aqueous solution (Etp-sol) and particles suspended in oil (the addition products of iodine and the ethyl esters of the fatty acids obtained from poppy-seed oil (Lipiodol) or sesame oil; Etp-oil). We also invest...

journal_title：Cancer chemotherapy and pharmacology

authors： Lee JS,Takahashi T,Hagiwara A,Yoneyama C,Itoh M,Sasabe T,Muranishi S,Tashima S

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:This exploratory phase II clinical trial evaluated the antitumor activity, safety profile and pharmacokinetics of PM00104 (Zalypsis(®)) 3 mg/m(2) 1 h every 3-week intravenous infusion in patients with advanced and/or metastatic urothelial carcinoma progressing after first-line platinum-based chemotherapy. METH...

journal_title：Cancer chemotherapy and pharmacology

authors： Castellano DE,Bellmunt J,Maroto JP,Font-Pous A,Morales-Barrera R,Ghanem I,Suarez C,Martín Lorente C,Etxaniz O,Capdevila L,Coronado C,Alfaro V,Siguero M,Fernández-Teruel C,Carles J

更新日期：2014-04-01 00:00:00

abstract：:Using flow cytometry and conventional spectrofluorimetry we have previously shown that chloroethylnitrosoureas (CNUs) can exhibit marked inhibition of cellular enzymes catalysing hydrolysis of fluorescein diacetate (FDA). More potent inhibition was seen for the carbamoylating CNUs, whereas alkylating agents were large...

journal_title：Cancer chemotherapy and pharmacology

authors： Dive C,Workman P,Watson JV

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:4'-Thio-β-D-arabinofuranosylcytosine (4'-thio-ara-C), which has shown a broad spectrum of antitumor activity against human tumor systems in mice and is undergoing clinical trials, was evaluated for cross-resistance to seven clinical agents in order to identify potentially useful guides for patient selection for...

journal_title：Cancer chemotherapy and pharmacology

authors： Waud WR,Gilbert KS,Secrist JA 3rd

更新日期：2011-08-01 00:00:00

abstract：:Unidirectional blood-brain barrier transfer of the lipophilic anticancer agents vincristine and vinblastine was studied in anesthetized rats, using an isolated, in situ brain perfusion technique. Drug binding to plasma constituents was also measured. Despite the high lipophilicity of these agents (the log octanol/phys...

journal_title：Cancer chemotherapy and pharmacology

authors： Greig NH,Soncrant TT,Shetty HU,Momma S,Smith QR,Rapoport SI

更新日期：1990-01-01 00:00:00

abstract：PURPOSE:ABT-888 inhibits poly(ADP-ribose) polymerase (PARP) and may enhance the efficacy of chemotherapy and radiation in CNS tumors. We studied the plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) of ABT-888 in a non-human primate (NHP) model that is highly predictive of human CSF penetration. METHODS:ABT-8...

journal_title：Cancer chemotherapy and pharmacology

authors： Muscal JA,Thompson PA,Giranda VL,Dayton BD,Bauch J,Horton T,McGuffey L,Nuchtern JG,Dauser RC,Gibson BW,Blaney SM,Su JM

更新日期：2010-02-01 00:00:00

abstract：PURPOSE:Mammalian target of rapamycin (mTOR) inhibitors like temsirolimus may result in undesirable AKT upregulation. Metformin inhibits mTOR through different mechanisms and may enhance temsirolimus's antitumor activity. We conducted an open-label phase I dose escalation trial of this drug combination in patients with...

journal_title：Cancer chemotherapy and pharmacology

authors： Khawaja MR,Nick AM,Madhusudanannair V,Fu S,Hong D,McQuinn LM,Ng CS,Piha-Paul SA,Janku F,Subbiah V,Tsimberidou A,Karp D,Meric-Bernstam F,Lu KH,Naing A

更新日期：2016-05-01 00:00:00

abstract：:This prospective, randomized, nonblind study comparing the antiemetic effectiveness of high-dose IV metoclopramide and high-dose IV dexamethasone was performed in 78 advanced cancer patients. Chemotherapeutic treatment consisted in cisplatin at a high-dose (120 mg/m2) (HD-CDDP) and at a low-dose (LD-CDDP), either alon...

journal_title：Cancer chemotherapy and pharmacology

authors： Frustaci S,Grattoni E,Tumolo S,Crivellari D,Figoli F,Galligioni E,Veronesi A,Tirelli U,Grigoletto E

更新日期：1986-01-01 00:00:00

abstract：PURPOSE:Capecitabine is an oral chemotherapeutic agent, already used in breast and colon cancer. Previous data showed encouraging results in the treatment of recurrent ovarian cancer. The aim of this study was to describe activity and toxicity of capecitabine in patients with platinum resistant or refractory ovarian ca...

journal_title：Cancer chemotherapy and pharmacology

authors： Pisano C,Morabito A,Sorio R,Breda E,Lauria R,Gebbia V,Scaltriti L,Scalone S,Zagonel V,Greggi S,Beneduce G,Losito S,Gallo C,Di Maio M,Forestieri V,Pignata S

更新日期：2009-10-01 00:00:00

abstract：PURPOSE:Although chemotherapeutic protocols that include chloroethylnitrosoureas (CENUs), such as 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) and 1, 3-bis(2-chloroethyl)-1-nitrosourea (BCNU), have been a mainstay of treatment for glioblastomas, the clinical outcomes ha...

journal_title：Cancer chemotherapy and pharmacology

authors： Narita Y,Asai A,Kuchino Y,Kirino T

更新日期：2000-01-01 00:00:00

abstract：PURPOSE:Busulfan (Bu) exposure is critical for efficacy and safety. Body weight (BW), or adjusted ideal body weight (AIBW)-based dosing (WBD) algorithm, has been used in hematopoietic stem cell transplantation (HSCT). A recently completed phase 2 study revealed that 33.6 % of the subjects were under-, or over-exposed, ...

journal_title：Cancer chemotherapy and pharmacology

authors： Wang Y,Kato K,Le Gallo C,Armstrong E,Rock E,Wang X

更新日期：2015-03-01 00:00:00

abstract：PURPOSE:Recently, based on results of the PACIFIC trial, durvalumab after chemoradiotherapy (CRT) became the standard therapy for unresectable stage III non-small cell lung cancer (NSCLC). However, in the PACIFIC trial, patients were recruited and randomized after CRT, and certain patients were considered ineligible af...

journal_title：Cancer chemotherapy and pharmacology

authors： Hosoya K,Fujimoto D,Kawachi H,Sato Y,Kogo M,Nagata K,Nakagawa A,Tachikawa R,Hiraoka S,Kokubo M,Tomii K

更新日期：2019-08-01 00:00:00

abstract：PURPOSE:The sequence bendamustine (B) + Irinotecan (I) followed by etoposide (E) + carboplatin (C) was hypothesized to increase progression-free survival (PFS) and overall survival (OS) in untreated extensive-disease small cell lung cancer (EDSCLC) patients compared to historical controls by exploiting mitotic catastro...

journal_title：Cancer chemotherapy and pharmacology

authors： Allendorf DJ,Bordoni RE,Grant SC,Saleh MN,Reddy VB,Jerome ML,Dixon PM,Miley DK,Singh KP,Robert F

更新日期：2015-11-01 00:00:00

abstract：PURPOSE:There is a need for effective chemotherapy protocols for gall bladder cancer (GBC). Gemcitabine has antitumor activity in pancreatic cancer. Oxaliplatin is effective in GI cancers. Based on evidence of synergy between these two, we designed this study to evaluate efficacy of this combination in unresectable GBC...

journal_title：Cancer chemotherapy and pharmacology

authors： Sharma A,Mohanti B,Raina V,Shukla N,Pal S,Dwary A,Deo S,Sahni P,Garg P,Thulkar S,DattaGupta S,Rath G

更新日期：2010-02-01 00:00:00

abstract：:Hexadecylphosphocholine (HPC) and octadecylphosphocholine (OPC) show very potent antitumor activity against autochthonous methylnitrosourea-induced mammary carcinomas in rats. The longer-chain and unsaturated homologue erucylphosphocholine (EPC) forms lamellar structures rather than micelles, but nonetheless exhibits ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kötting J,Berger MR,Unger C,Eibl H

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:Epigenetic silencing of tumor suppressor genes (TSGs) by aberrant DNA methylation and chromatin deacetylation provides interesting targets for chemotherapeutic intervention by inhibitors of these events. 5-Aza-2'-deoxycytidine (decitabine, 5AZA-CdR) is a potent demethylating agent, which can reactivate TSGs sil...

journal_title：Cancer chemotherapy and pharmacology

authors： Hurtubise A,Momparler RL

更新日期：2006-11-01 00:00:00

abstract：:The chemotherapeutic effects of all-trans-retinoic acid (atRA) are mediated by the retinoic acid receptor beta (RARbeta), but RARbeta expression is reduced in a number of head and neck carcinoma (HNSCC) cells which causes resistance to RA treatment in half the patients with HNSCC. The possible mechanism for the reduce...

journal_title：Cancer chemotherapy and pharmacology

authors： Whang YM,Choi EJ,Seo JH,Kim JS,Yoo YD,Kim YH

更新日期：2005-11-01 00:00:00

abstract：BACKGROUND:Camptothecin (CPT) is an anticancer agent that kills cells by converting DNA topoisomerase I into a DNA-damaging agent. Although CPT and its derivatives are now being used to treat tumors in a variety of clinical protocols, the low water solubility of the drug and its unique pharmacodynamics and reactivity i...

journal_title：Cancer chemotherapy and pharmacology

authors： Minko T,Paranjpe PV,Qiu B,Lalloo A,Won R,Stein S,Sinko PJ

更新日期：2002-08-01 00:00:00

abstract：:We have recently demonstrated that continuous-infusion (CI) 5-fluorouracil (FU) eradicates human colon carcinoma cells made resistant to bolus FU in vitro. In addition, in the same experimental system, the mechanisms of resistance to pulse and CI FU were found to be different. These observations led us to test the cli...

journal_title：Cancer chemotherapy and pharmacology

authors： Mori A,Bertoglio S,Guglielmi A,Aschele C,Bolli E,Tixi L,Rosso R,Sobrero A

更新日期：1993-01-01 00:00:00